PARIS (Reuters) – French health authority HAS said on Friday that Novavax’s Nuvaxovid and Janssen’s COVID-19 vaccine offered an efficient alternative for people hesitant about RNA-based vaccines or who cannot take these for medical reasons.
HAS said RNA-based vaccines remain the preferred option, but that the two other vaccines should also be part of France’s vaccination strategy.
(Reporting by Jean-Stephane Brosse, writing by GV De Clercq, Editing by Catherine Evans)
